These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3567978)

  • 1. Androgen therapy in the treatment of refractory epithelial ovarian cancer.
    Kavanagh JJ; Wharton JT; Roberts WS
    Cancer Treat Rep; 1987 May; 71(5):537-8. PubMed ID: 3567978
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias.
    Scand J Haematol; 1986 Apr; 36(4):346-52. PubMed ID: 2872720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of adrenalectomy and androgen in disseminated mammary carcinoma.
    Dao TL; Nemoto T
    Surg Gynecol Obstet; 1965 Dec; 121(6):1257-62. PubMed ID: 4158865
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical effect of fluoxymesterone in the treatment of recurrent and progressive breast neoplasms].
    Takaya O
    Horumon To Rinsho; 1977 Dec; 25(12):1371-84. PubMed ID: 598046
    [No Abstract]   [Full Text] [Related]  

  • 5. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen therapy.
    Longson D
    Practitioner; 1972 Mar; 208(245):338-48. PubMed ID: 4557109
    [No Abstract]   [Full Text] [Related]  

  • 7. Teniposide in refractory ovarian cancer: a phase II study.
    Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
    Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
    [No Abstract]   [Full Text] [Related]  

  • 8. Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
    Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; FALKSON HC
    Cancer Chemother Rep; 1974; 58(6):939-41. PubMed ID: 4615788
    [No Abstract]   [Full Text] [Related]  

  • 9. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 10. Ifosfamide treatment of advanced ovarian cancer.
    Yazigi R; Wild R; Madrid J; Arraztoa J
    Obstet Gynecol; 1984 Feb; 63(2):163-6. PubMed ID: 6694809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical trial of diaziquone in the treatment of patients with epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Slayton RE; Blessing JA; Sutton GP; Homesley HD; Park R
    Cancer Treat Rep; 1986 Feb; 70(2):309-10. PubMed ID: 3948196
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen therapy for advanced ovarian cancer.
    Schwartz PE; Keating G; MacLusky N; Naftolin F; Eisenfeld A
    Obstet Gynecol; 1982 May; 59(5):583-8. PubMed ID: 7070729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic drug and hormone therapy after adrenalectomy for advanced breast cancer.
    Keating JL; Yonemoto RH; Byron RL
    Surg Gynecol Obstet; 1968 Sep; 127(3):538-42. PubMed ID: 4969618
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent Iv homoharringtonine for the treatment of refractory epithelial carcinoma of the ovary: a phase II trial.
    Kavanagh JJ; Gershenson DM; Copeland LJ; Wharton JT; Rutledge FN; Krakoff IH
    Cancer Treat Rep; 1984 Dec; 68(12):1503-4. PubMed ID: 6542450
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells.
    Evangelou A; Letarte M; Jurisica I; Sultan M; Murphy KJ; Rosen B; Brown TJ
    Cancer Res; 2003 May; 63(10):2416-24. PubMed ID: 12750261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen therapy of epithelial ovarian cancer.
    Shirey DR; Kavanagh JJ; Gershenson DM; Freedman RS; Copeland LJ; Jones LA
    Obstet Gynecol; 1985 Oct; 66(4):575-8. PubMed ID: 4047546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of bleomycin in patients with advanced epithelial ovarian cancer.
    Blackledge G; Lawton F; Buckley H; Crowther D
    Cancer Treat Rep; 1984 Mar; 68(3):549-50. PubMed ID: 6200221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between in vitro and in vivo response to androgens in patients with aplastic anemia.
    Kamamoto T; Ohkubo T; Yamagishi M; Yoshida Y; Uchino H
    Int J Cell Cloning; 1984 May; 2(3):173-84. PubMed ID: 6736687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of mitoxantrone in epithelial ovarian cancer.
    Lawton F; Blackledge G; Mould J; Latief T; Watson R; Chetiyawardana AD
    Cancer Treat Rep; 1987 Jun; 71(6):627-9. PubMed ID: 3581101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.